Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lithium dose prediction based on 24 hours single dose levels: a prospective evaluation.

N Gervasoni1, M-P Zona-Favre, Ch Osiek

  • 1Département de Psychiatrie, Clinique de Psychiatrie Adulte-Programme Dépression, Hôpitaux Universitaires de Genève, Domaine de Belle-Idée, 16-18, bd Saint-Georges, CH-1205 Geneva, Switzerland. Nicola.Gervasoni@hcuge.ch

Pharmacological Research
|October 7, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial complex I activity in microglia sustains neuroinflammation.

Nature·2024
Same author

Mitochondrial reverse electron transport in myeloid cells perpetuates neuroinflammation.

bioRxiv : the preprint server for biology·2024
Same author

Endogenous CO<sub>2</sub> ice mixture on the surface of Europa and no detection of plume activity.

Science (New York, N.Y.)·2023
Same author

Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression.

L'Encephale·2023
Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Hyper/neuroinflammation in COVID-19 and suicide etiopathogenesis: Hypothesis for a nefarious collision?

Neuroscience and biobehavioral reviews·2022

This study introduces a pharmacokinetic prediction test for lithium dosing. The test aims to adjust lithium dosage early in treatment, with 51% of patients achieving target plasma levels.

Area of Science:

  • Pharmacology
  • Clinical Chemistry

Background:

  • Lithium is a mood stabilizer requiring careful dosing to maintain therapeutic levels and avoid toxicity.
  • Traditional lithium dosing requires waiting for steady-state plasma concentrations (typically one week) before dose adjustment.
  • Pharmacokinetic (PK) prediction tests offer a potential method for earlier and more precise lithium posology.

Purpose of the Study:

  • To evaluate the utility of a PK prediction test for optimizing lithium posology.
  • To determine the feasibility of adapting lithium dosage by the second day of treatment.
  • To assess the proportion of patients achieving a target plasma lithium level of 0.8 +/- 0.1 mmol/L.

Main Methods:

  • A PK prediction test was utilized, based on a single plasma lithium determination 24 hours after an initial dose.

Related Experiment Videos

  • The test aimed to predict and adapt the patient's lithium dosage for the subsequent day.
  • Thirty-one patients with bipolar disorder were enrolled; data from 29 were analyzed.

    • Main Results:

    • The PK prediction test successfully placed 51% of patients within the targeted plasma lithium concentration range (0.8 +/- 0.1 mmol/L).
    • The test facilitated the use of higher lithium doses compared to standard fixed doses, potentially improving efficacy.
    • No control group was used, limiting direct comparison of outcomes.

    Conclusions:

    • The PK prediction test shows promise for early and individualized lithium dosing.
    • This approach may allow for more aggressive dosing strategies while managing the risk of toxicity.
    • Further research, including controlled trials, is warranted to confirm the clinical benefits.